• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重增加与整合酶抑制剂。

Weight gain and integrase inhibitors.

机构信息

Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina.

University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

出版信息

Curr Opin Infect Dis. 2020 Feb;33(1):10-19. doi: 10.1097/QCO.0000000000000616.

DOI:10.1097/QCO.0000000000000616
PMID:31789693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7433018/
Abstract

PURPOSE OF REVIEW

Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs). This article comprehensively reviews available data and summarizes our current understanding of the topic.

RECENT FINDINGS

Recent studies support the concept that weight gain and treatment emergent obesity are worse with INSTI-based regimens, particularly dolutegravir. Women and nonwhites appear to be the most at risk, and the accompanying nucleoside reverse transcriptase inhibitor may play a role. Lipohypertrophy, an abnormal accumulation of visceral fat and/or ectopic fat depots, continues to be a problem among PLWH, but the role of INSTIs is inconsistent. The pathogenesis of weight gain and changes in body composition in HIV, especially with INSTIs, is poorly understood but may lead to serious comorbidities, such as cardiovascular disease and diabetes.

SUMMARY

Although INSTI-based regimens are highly efficacious for viral suppression, they appear to cause more weight gain and treatment emergent obesity than non-INSTI-based regimens and may increase the risk of weight-related comorbidities. More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication.

摘要

目的综述

抗逆转录病毒治疗(ART)开始后,HIV 感染者(PLWH)体重增加和肥胖是一个严重的问题,但整合酶抑制剂(INSTIs)可能会使问题恶化。本文全面回顾了现有数据,总结了我们目前对这一主题的理解。

最新发现

最近的研究支持了这样一种概念,即 INSTI 为基础的治疗方案,尤其是多替拉韦,会导致体重增加和治疗后肥胖的风险增加。女性和非白人似乎风险最高,伴随的核苷逆转录酶抑制剂可能起作用。脂肪代谢障碍,即内脏脂肪和/或异位脂肪堆积异常,仍是 PLWH 的一个问题,但 INSTIs 的作用并不一致。HIV 中体重增加和身体成分变化的发病机制,特别是与 INSTIs 相关的机制,尚不清楚,但可能导致严重的合并症,如心血管疾病和糖尿病。

总结

尽管 INSTI 为基础的治疗方案在病毒抑制方面非常有效,但与非 INSTI 为基础的治疗方案相比,它们似乎会导致更多的体重增加和治疗后肥胖,并可能增加与体重相关的合并症的风险。需要进一步研究来了解 INSTIs 在 PLWH 中导致体重增加的发病机制,以预防这一严重并发症。

相似文献

1
Weight gain and integrase inhibitors.体重增加与整合酶抑制剂。
Curr Opin Infect Dis. 2020 Feb;33(1):10-19. doi: 10.1097/QCO.0000000000000616.
2
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.在美国和加拿大的一个大型观察性队列中,与非核苷类逆转录酶抑制剂或蛋白酶抑制剂相比,初治 HIV 感染者开始使用整合酶抑制剂后体重增加。
J Int AIDS Soc. 2020 Apr;23(4):e25484. doi: 10.1002/jia2.25484.
3
Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.在开始使用整合酶抑制剂后,一名 HIV 感染者的内脏脂肪组织增加。
Int J STD AIDS. 2020 Dec;31(14):1407-1410. doi: 10.1177/0956462420955075. Epub 2020 Oct 21.
4
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.初治人群开始使用多替拉韦为基础的抗逆转录病毒治疗时体重增加较多。
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. doi: 10.1093/cid/ciz407.
5
Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.简报:整合酶链转移抑制剂与 HIV 感染者新发心血管疾病风险降低相关。
J Acquir Immune Defic Syndr. 2020 Aug 1;84(4):396-399. doi: 10.1097/QAI.0000000000002357.
6
Nothing is perfect: the safety issues of integrase inhibitor regimens.没有什么是完美的:整合酶抑制剂治疗方案的安全性问题。
Expert Opin Drug Saf. 2020 Jun;19(6):683-694. doi: 10.1080/14740338.2020.1764531. Epub 2020 May 22.
7
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.简要报告:在当前治疗时代,ART 初治的 HIV 感染者在开始 ART 后体重增加。
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):339-343. doi: 10.1097/QAI.0000000000002556.
8
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.整合酶抑制剂治疗与代谢综合征和糖尿病风险。
Curr Opin Infect Dis. 2021 Feb 1;34(1):16-24. doi: 10.1097/QCO.0000000000000695.
9
Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.肥胖改变了女性 HIV 感染者体内雷替拉韦和多替拉韦与头发浓度和体重增加的关系。
AIDS Res Hum Retroviruses. 2023 Dec;39(12):644-651. doi: 10.1089/AID.2022.0185. Epub 2023 Jun 20.
10
Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.HIV感染者开始、换用及停用整合酶链转移抑制剂时的体重变化
AIDS Patient Care STDS. 2023 Mar;37(3):131-137. doi: 10.1089/apc.2022.0203. Epub 2023 Feb 21.

引用本文的文献

1
Bone health in a U.K. cohort of youth living with perinatally acquired HIV-1: a longitudinal study.英国一组围产期感染HIV-1的青年的骨骼健康:一项纵向研究。
J Int AIDS Soc. 2025 Sep;28(9):e70029. doi: 10.1002/jia2.70029.
2
Differential effects of switching to integrase strand transfer inhibitors on the gut microbiota and markers of HIV disease progression.转换为整合酶链转移抑制剂对肠道微生物群及HIV疾病进展标志物的不同影响。
BMC Microbiol. 2025 Sep 1;25(1):569. doi: 10.1186/s12866-025-04313-9.
3
Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks.在长达96周的随机试验中,使用多替拉韦或对照抗逆转录病毒疗法时的高血压及血压变化。
J Antimicrob Chemother. 2025 Sep 3;80(9):2375-2383. doi: 10.1093/jac/dkaf212.
4
Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany.转换为基于多拉韦林的抗逆转录病毒疗法的有效性:德国的一项真实世界研究。
HIV Med. 2025 Aug;26(8):1289-1299. doi: 10.1111/hiv.70061. Epub 2025 Jul 4.
5
The Role of Nutrition in HIV-Associated Neurocognitive Disorders: Mechanisms, Risks, and Interventions.营养在HIV相关神经认知障碍中的作用:机制、风险与干预措施
Life (Basel). 2025 Jun 19;15(6):982. doi: 10.3390/life15060982.
6
Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.感染艾滋病毒者与常见非艾滋病定义癌症患者的慢性健康状况负担
J Natl Compr Canc Netw. 2025 Jun 9;23(7):e257018. doi: 10.6004/jnccn.2025.7018.
7
Metabolic dysfunction-associated steatotic liver disease in people with HIV.HIV感染者中与代谢功能障碍相关的脂肪性肝病
Curr Opin HIV AIDS. 2025 Jul 1;20(4):350-358. doi: 10.1097/COH.0000000000000952. Epub 2025 May 21.
8
Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1.多替拉韦/阿巴卡韦/拉米夫定用于急性HIV-1感染可快速抑制并恢复CD4 T细胞亚群,且不会加速潜伏性HIV-1的衰减。
Open Forum Infect Dis. 2025 Apr 24;12(5):ofaf247. doi: 10.1093/ofid/ofaf247. eCollection 2025 May.
9
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.在HIV-RNA检测不到的艾滋病毒感染者中选定的合并症与抗逆转录病毒治疗转换的概率:意大利的一项回顾性分析
J Antimicrob Chemother. 2025 Jul 1;80(7):1849-1859. doi: 10.1093/jac/dkaf137.
10
Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate.与替诺福韦酯相比,丙酚替诺福韦可促进体重增加并损害内脏脂肪组织中与脂肪酸代谢相关的信号通路。
Antiviral Res. 2025 May;237:106151. doi: 10.1016/j.antiviral.2025.106151. Epub 2025 Mar 26.

本文引用的文献

1
Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.抗逆转录病毒疗法:基于治疗起始时体重指数的 HIV 感染者治疗后趋势。
Mil Med. 2021 Feb 26;186(3-4):279-285. doi: 10.1093/milmed/usaa416.
2
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加:随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
3
Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.女性使用整合酶抑制剂与体重增加相关。
Clin Infect Dis. 2020 Jul 27;71(3):593-600. doi: 10.1093/cid/ciz853.
4
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.多替拉韦加利伟酯联合两种不同的替诺福韦前药治疗 HIV。
N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24.
5
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.基于多替拉韦的或基于低剂量依非韦伦的方案治疗人类免疫缺陷病毒 1 型。
N Engl J Med. 2019 Aug 29;381(9):816-826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24.
6
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.卡博特韦在 HPTN 077 中与未感染人类免疫缺陷病毒的个体的体重增加无关。
Clin Infect Dis. 2020 Jan 2;70(2):319-322. doi: 10.1093/cid/ciz439.
7
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.初治人群开始使用多替拉韦为基础的抗逆转录病毒治疗时体重增加较多。
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. doi: 10.1093/cid/ciz407.
8
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯固定剂量复方片与多替拉韦加拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初治:96 周随机、双盲、多中心、3 期、非劣效性试验结果。
Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.
9
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于初治 HIV-1 感染:来自一项随机、双盲、多中心、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5.
10
Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications.肥胖与人类免疫缺陷病毒感染者的脂肪代谢:免疫发病机制与临床意义。
J Infect Dis. 2019 Jul 2;220(3):420-431. doi: 10.1093/infdis/jiz118.